Is Circulating Tumor DNA (Ctdna) Use Ready For Prime Time? Applications and Challenges of Ctdna in the Era of Precision OncologyDavis AA, Chae YK* and Giles FJ
Department of Medicine, Division of Hematology Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
- *Corresponding Author:
- Young Kwang Chae
Department of Medicine
Division of Hematology Oncology
Feinberg School of Medicine
Northwestern University, Chicago, IL 60611, USA
Tel: 312 926 4248
Fax: 312 695 0370
E-mail: [email protected]
Received Date: March 26, 2017; Accepted Date: April 17, 2017; Published Date: April 22, 2017
Citation: Davis AA, Chae YK, Giles FJ (2017) Is Circulating Tumor DNA (Ctdna) Use Ready For Prime Time? Applications and Challenges of Ctdna in the Era of Precision Oncology. Chemo Open Access 6:230. doi: 10.4172/2167-7700.1000230
Copyright: © 2017 Davis AA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
“Liquid biopsies” have emerged as a tool to monitor genomic alterations in the peripheral blood . Cell-free DNA consists of noncancerous nucleic acids and circulating tumor DNA (ctDNA). The proportion of ctDNA depends on the tumor cell of origin and stage of malignancy [2-5]. Peripheral blood biopsies can detect single nucleotide variants, indels, copy number variants, rearrangements and fusions, non-invasively, avoiding risk associated with repeat tissue biopsies. However, concerns remain with respect to ctDNA adequately reflecting tumor heterogeneity, thresholds for detection, and lack of randomized control trials to validate improved survival outcomes. As a result, further data are necessary to compare sequencing data between tissue and blood biopsies to validate clinical utility.